Migraine is a chronic pain condition that affects 12% of the population. Currently, the most effective treatments are the triptans, but they are limited in their efficacy and have potentially deleterious cardiovascular complications. On the basis of basic science studies over the past decade, a new generation of anti-migraine drugs is now being developed. At the forefront of these studies is a new calcitonin gene-related peptide (CGRP) receptor antagonist that is as effective as triptans in the acute treatment of migraines, without the cardiovascular effects. This review will address the likely mechanisms and therapeutic potential of CGRP receptor antagonists. © 2006 Elsevier Ltd. All rights reserved.
de Prado, B. M., & Russo, A. F. (2006, June). CGRP receptor antagonists: A new frontier of anti-migraine medications. Drug Discovery Today: Therapeutic Strategies. https://doi.org/10.1016/j.ddstr.2006.11.003